Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ANI Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. ANI Pharmaceuticals shares (ANIP) are listed on the NASDAQ and all prices are listed in US Dollars. ANI Pharmaceuticals employs 338 staff and has a trailing 12-month revenue of around USD$199.2 million.
|Latest market close||USD$30.57|
|52-week range||USD$23.55 - USD$68.19|
|50-day moving average||USD$28.8021|
|200-day moving average||USD$29.4699|
|Wall St. target price||USD$38.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.337|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-2.36%|
|1 month (2020-12-16)||-0.62%|
|3 months (2020-10-15)||4.66%|
|6 months (2020-07-15)||3.42%|
|1 year (2020-01-15)||-48.66%|
|2 years (2019-01-15)||-42.51%|
|3 years (2018-01-12)||72.3|
|5 years (2016-01-15)||35.67|
Valuing ANI Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ANI Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ANI Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, ANI Pharmaceuticals shares trade at around 78x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ANI Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ANI Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ANI Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.1 million.
The EBITDA is a measure of a ANI Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$199.2 million|
|Gross profit TTM||USD$143.4 million|
|Return on assets TTM||-3.16%|
|Return on equity TTM||-11.64%|
|Market capitalisation||USD$346 million|
TTM: trailing 12 months
There are currently 613,024 ANI Pharmaceuticals shares held short by investors – that's known as ANI Pharmaceuticals's "short interest". This figure is 2.1% up from 600,659 last month.
There are a few different ways that this level of interest in shorting ANI Pharmaceuticals shares can be evaluated.
ANI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of ANI Pharmaceuticals shares currently shorted divided by the average quantity of ANI Pharmaceuticals shares traded daily (recently around 59924.144672532). ANI Pharmaceuticals's SIR currently stands at 10.23. In other words for every 100,000 ANI Pharmaceuticals shares traded daily on the market, roughly 10230 shares are currently held short.
However ANI Pharmaceuticals's short interest can also be evaluated against the total number of ANI Pharmaceuticals shares, or, against the total number of tradable ANI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ANI Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 ANI Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable ANI Pharmaceuticals shares, roughly 75 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ANI Pharmaceuticals.
Find out more about how you can short ANI Pharmaceuticals stock.
We're not expecting ANI Pharmaceuticals to pay a dividend over the next 12 months.
ANI Pharmaceuticals's shares were split on a 1:6 basis on 18 July 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ANI Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for ANI Pharmaceuticals shares which in turn could have impacted ANI Pharmaceuticals's share price.
Over the last 12 months, ANI Pharmaceuticals's shares have ranged in value from as little as $23.55 up to $68.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ANI Pharmaceuticals's is 1.3391. This would suggest that ANI Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company offers pharmaceuticals for the treatment of breast cancer, hypertension, ventricular arrhythmias, stage D2 metastatic carcinoma of the prostate, depression, diarrhea, infections, vasomotor symptoms of menopause, pain caused by osteoarthritis and rheumatoid arthritis, epilepsy, arrhythmia, obsessive-compulsive disorder and social anxiety disorder, ulcerative colitis, salt and fluid retention, manic episodes of bipolar disorder, ulcerative colitis, proctosigmoiditis, ocular conditions, metastatic prostate cancer, arrhythmia, migraine headache, and enterocolitis caused by staphylococcus aureus. It also provides aspirin and extended-release dipyridamole; Cholestyramine, an adjunctive therapy to diet for the reduction of elevated serum cholesterol; Ezetimibe-Simvastatin to lower high cholesterol and triglyceride levels; Fenofibrate, a peroxisome proliferator receptor alpha activator; Hydrocortisone rectal cream for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Morphine Sulfate, an oral solution for acute and chronic pain management; Nimodipine to enhance neurological outcomes; and Terbutaline Sulfate for the prevention and reversal of bronchospasm. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.